Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Laura N Eadie; Elias Lagonik; Elyse C Page; Caitlin E Schutz; Susan L Heatley; Barbara J McClure; Michelle O Forgione; David T Yeung; Timothy P Hughes; Deborah L White

doi:10.1182/blood.2024024776

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Blood. 2024 Aug 29;144(9):1022-1026. doi: 10.1182/blood.2024024776.

Authors

Laura N Eadie^{1

2}, Elias Lagonik^{1

3}, Elyse C Page^{1

2}, Caitlin E Schutz¹, Susan L Heatley^{1

2}, Barbara J McClure^{1

2}, Michelle O Forgione^{1

2}, David T Yeung^{1

2

4

5}, Timothy P Hughes^{1

2

4

5}, Deborah L White^{1

2

4}

Affiliations

¹ Blood Cancer Program, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.
² Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia.
³ Faculty of Sciences, Engineering and Technology, The University of Adelaide, Adelaide, Australia.
⁴ Australasian Leukaemia and Lymphoma Group, Melbourne, Australia.
⁵ Haematology Department, Royal Adelaide Hospital, Adelaide, Australia.

PMID: 38848536
DOI: 10.1182/blood.2024024776

No abstract available

Publication types

Letter

MeSH terms

Fusion Proteins, bcr-abl / antagonists & inhibitors
Fusion Proteins, bcr-abl / genetics
Humans
Niacinamide / analogs & derivatives
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Protein Kinase Inhibitors* / pharmacology
Protein Kinase Inhibitors* / therapeutic use
Proto-Oncogene Proteins c-abl* / antagonists & inhibitors
Proto-Oncogene Proteins c-abl* / genetics
Pyrazoles
src Homology Domains / genetics

Substances

asciminib
ABL1 protein, human
Proto-Oncogene Proteins c-abl
Protein Kinase Inhibitors
Fusion Proteins, bcr-abl
Niacinamide
Pyrazoles